XRCC2 and ovarian carcinoma: With regard to stages of ovarian carcinoma (Table 2), both XRCC2 and XRCC9 with high expression were considered as significantly favorable productive factors of PFS and OS in stage III+IV ovarian carcinoma patients (XRCC2, PFS: HR=0.78 (0.67-0.9), P=0.0010, OS: HR=0.72 (0.6-0.85), P=0.0000; XRCC9, PFS: HR=0.77 (0.67-0.88), P=0.0003, OS: HR=0.79 (0.68-0.92), P=0.0022).